Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada

HERZLIYA, Israel and CALGARY, AB, Aug. 22, 2025 /CNW/ -- Innocan Pharma Corporation (CNSX:INNO.CN) (FSE:IP4) (OTC-BB:INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that during the PAINWeek conference 2025, it will showcase a poster outlining key data on LPT-CBD pharmacokinetics and efficacy along with the recently published  narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: https://doi.org/10.7759/cureus.81577).  PAINWeek is the premier US national conference on pain management, taking place this year in Las Vegas, Nevada, from September 2–5, 2025. The poster will be showcased during the scientific poster reception on September 4 (Poster #29), presented by Joseph V. Pergolizzi, Jr., MD, MBA, NEMA Research, a key member of Innocan's advisory board.